TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT05221359: An Open Label, Monocentric, Pilot Study Evaluating Safety of ExOlin® in Patients With Poorly Controlled Type 1 Diabetes With High Glucose Fluctuations, Prone to Severe Hypoglycemia

Sponsor: Defymed · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 20 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$929,600

Rescue Site Savings

+$597,600

Unlock Full NCT05221359 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05221359 Rescue Dossier →